Wall Street analyst estimates for Supernus Pharmaceuticals, Inc. (SUPN): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 9 |
| Hold | 5 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 14 |
| Avg rating (1-5) | 0.64 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-03 | $0.61 | ||
| 2026-08-03 | $0.54 | $0.42 | +27.8% |
| 2026-05-05 | $0.59 | $0.28 | +110.7% |
| 2026-02-24 | $0.92 | $0.28 | +228.6% |
| 2025-11-04 | $1.01 | $0.82 | +23.2% |
| 2025-08-05 | $0.91 | $0.47 | +93.6% |
| 2025-05-06 | $0.42 | $0.38 | +10.5% |
| 2025-02-25 | $0.75 | $0.46 | +63.0% |
Valuation Ratios
| Price / Book | 2.41 |
| EV / EBITDA | -147.59 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $215.0M | $302.2M | $408.9M | $392.8M | $520.4M | $579.8M | $667.2M | $607.5M | $661.8M | $719.0M |
| Cost of Revenue | $12.0M | $15.2M | $15.4M | $16.7M | $52.5M | $75.1M | $87.2M | $83.8M | $77.9M | $74.6M |
| Gross Profit | $203.0M | $287.0M | $393.5M | $376.1M | $467.9M | $504.7M | $580.0M | $523.7M | $583.9M | $644.4M |
| Research & Development | $42.8M | $49.6M | $89.2M | $69.1M | $76.0M | $90.5M | $74.6M | $91.6M | $108.8M | $106.2M |
| Selling, General & Admin | $106.0M | $137.9M | $159.9M | $158.4M | $200.7M | $304.8M | $377.2M | $336.4M | $335.8M | $485.6M |
| Operating Expenses | $148.8M | $187.5M | $249.1M | $227.5M | $294.2M | $418.7M | $533.9M | $529.0M | $502.2M | $681.3M |
| Operating Income | $54.2M | $99.5M | $144.4M | $148.6M | $173.7M | $86.0M | $46.1M | -$5.3M | $81.7M | -$36.9M |
| EBITDA | $56.6M | $107.7M | $151.5M | $180.4M | $210.5M | $129.2M | $153.4M | $90.0M | $178.3M | $42.5M |
| Interest Expense | $5.1M | $1.6M | $18.1M | $22.7M | $23.8M | $23.4M | $7.1M | $2.4M | 0 | 0 |
| Pre-tax Income | $50.4M | $100.6M | $140.2M | $147.5M | $168.6M | $73.2M | $60.7M | $2.8M | $97.9M | -$49.0M |
| Income Tax | -$40.9M | $43.3M | $29.2M | $34.4M | $41.7M | $19.8M | $32,000 | $1.5M | $24.0M | -$10.5M |
| Net Income | $91.2M | $57.3M | $111.0M | $113.1M | $127.0M | $53.4M | $60.7M | $1.3M | $73.9M | -$38.5M |
| EPS | $1.84 | $1.13 | $2.13 | $2.16 | $2.41 | $1.01 | $1.13 | $0.02 | $1.34 | $-0.68 |
| EPS (Diluted) | $1.76 | $1.08 | $2.05 | $2.10 | $2.36 | $0.98 | $1.04 | $0.02 | $1.32 | $-0.68 |
| Shares Outstanding (Diluted) | $51.7M | $53.3M | $54.1M | $53.8M | $53.7M | $54.4M | $61.7M | $55.5M | $56.0M | $56.5M |
Price
| Price | $43.04 |
| Market Cap | $2.5B |
| Exchange | NASDAQ |
| Country | US |
Related companies: AMRX · BHC · CGON · GRAL · HCM · INDV
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of SUPN: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks